486 related articles for article (PubMed ID: 16170185)
1. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
3. Regulation of c-Raf-1: therapeutic implications.
Beeram M; Patnaik A; Rowinsky EK
Clin Adv Hematol Oncol; 2003 Aug; 1(8):476-81. PubMed ID: 16258435
[TBL] [Abstract][Full Text] [Related]
4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
5. Raf pathway inhibitors in oncology.
Bollag G; Freeman S; Lyons JF; Post LE
Curr Opin Investig Drugs; 2003 Dec; 4(12):1436-41. PubMed ID: 14763129
[TBL] [Abstract][Full Text] [Related]
6. RAF protein-serine/threonine kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
[TBL] [Abstract][Full Text] [Related]
7. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
8. Is B-Raf a good therapeutic target for melanoma and other malignancies?
Madhunapantula SV; Robertson GP
Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R
Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
[TBL] [Abstract][Full Text] [Related]
10. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
11. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
12. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
13. Hyperactive Ras in developmental disorders and cancer.
Schubbert S; Shannon K; Bollag G
Nat Rev Cancer; 2007 Apr; 7(4):295-308. PubMed ID: 17384584
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
16. Raf kinase inhibitors in oncology.
Strumberg D; Seeber S
Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
[TBL] [Abstract][Full Text] [Related]
17. Second nature: biological functions of the Raf-1 "kinase".
Baccarini M
FEBS Lett; 2005 Jun; 579(15):3271-7. PubMed ID: 15943972
[TBL] [Abstract][Full Text] [Related]
18. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
19. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
Garnett MJ; Rana S; Paterson H; Barford D; Marais R
Mol Cell; 2005 Dec; 20(6):963-9. PubMed ID: 16364920
[TBL] [Abstract][Full Text] [Related]
20. B-Raf kinase inhibitors for cancer treatment.
Li N; Batt D; Warmuth M
Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
